This CME program will feature content presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. Four expert faculty will analyze recent therapeutic advances in the treatment and management of patients with dylispidemia, as well as the role of PCSK9 inhibitors in lowering LDL-C and reducing cardiovascular risk in those patients. Long-term cardiovascular efficacy and safety data will be reviewed, and clinical relevance debated. Further, the expert faculty will outline strategies for utilizing the inter-professional team and incorporating recent data into individualized treatment plans. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of dyslipidemia as it relates to improving outcomes and quality of life in clinical practice.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with dyslipidemia.
- Review the role of PCSK9 inhibitors in lowering LDL-C in high cardiovascular risk patient populations
- Examine long-term cardiovascular efficacy and safety data of PCSK9 inhibitors for the treatment of dyslipidemia presented at ESC 2017
- Incorporate recent data into individualized treatment plans to reduce cardiovascular risk and improve outcomes for patients with dyslipidemia
Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Brigham and Women’s Hospital